Eli Lilly Announces Nearly $4 Billion in Vaccine Acquisitions

CNBC reported Tuesday that Eli Lilly has agreed to acquire three clinical-stage vaccine biotechs for a combined total approaching $4 billion. The move marks a significant strategic pivot for the pharmaceutical giant beyond its dominant weight-loss and diabetes portfolio.

Three Deals, Three Disease Targets

Lilly struck separate agreements to purchase Curevo for $1.5 billion, LimmaTech Biologics for $780 million, and Vaccine Company for $1.55 billion. Each firm brings a distinct pipeline to the table. Curevo has developed a shingles-prevention vaccine engineered with a synthetic adjuvant. The design aims to improve tolerability and reduce adverse side effects compared with existing options.

LimmaTech focuses on bacterial pathogens where antimicrobial resistance is a growing clinical concern. Its work targets sexually transmitted infections, including gonorrhoeae and chlamydia strains that are increasingly difficult to treat. Vaccine Company contributes a nanoparticle delivery platform capable of transporting drugs, genetic material, or diagnostic sensors inside the body. One key target is the Epstein-Barr virus, which has been linked to multiple sclerosis and certain cancers.

Also Read: Novo Nordisk’s Wegovy Loses Ground as Competition Heats Up

A Deliberate Shift Away From Treatment

Lilly’s chief scientific and product officer Daniel M. Skovronsky framed the acquisitions in explicitly preventive terms. He said the strategy reflects a goal to stop disease before it starts rather than manage outcomes after the fact, according to CNBC.

The deals signal that Lilly is using cash generated by its blockbuster obesity and diabetes franchise to build scale in infectious disease. The company’s flagship injectable therapies Zepbound and Mounjaro each generated more than $4 billion in first-quarter U.S. revenue alone.

Background: Lilly’s GLP-1 Dominance Funds Expansion

Eli Lilly has spent the past two years consolidating leadership in the obesity drug market. The company held a 60.1% share of the U.S. obesity drug segment in the first quarter of 2026. Rival Novo Nordisk, maker of Wegovy, held the remaining 39.4%. Lilly also recently launched Foundayo, a newly approved oral GLP-1 obesity pill, in the second quarter, adding another competitive layer to its metabolic portfolio.

Markets React With Measured Optimism

Lilly shares gained roughly 0.9% shortly after the opening bell on Tuesday. The modest move suggests investors view the acquisitions as strategically sensible rather than urgently transformative. The cash-heavy nature of all three deals leaves little ambiguity around deal structure or dilution risk.

Read Next: Novo Nordisk Fights Back as Eli Lilly Widens Obesity Drug Lead